Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2436442 | 0.90 | LTB4R (0.53) | SMN1; SMN2MAOBCNR1CNR2HRH3 | |
| SCHEMBL2434205 | 0.85 | NR4A2 (0.58) | NPC1RAB9ASMN1; SMN2MAOBTSHR | |
| SCHEMBL2436240 | 0.83 | NR4A2 (0.62) | RAB9ASMN1; SMN2MAOBTSHRL3MBTL1 | |
| SCHEMBL2886621 | 0.80 | MEN1 (0.65) | SMN1; SMN2MAOBTSHRL3MBTL1CNR1 | |
| SCHEMBL2434118 | 0.78 | LRRK2 (0.49) | L3MBTL1LMNAKMT2AHPGD | |
| SCHEMBL2434968 | 0.76 | NR4A2 (0.65) | SMN1; SMN2TSHRL3MBTL1NR4A2LMNA | |
| SCHEMBL2882506 | 0.75 | MEN1 (0.65) | SMN1; SMN2LTB4RLTB4R2LMNAKMT2A | |
| SCHEMBL28683780 | 0.75 | MAOB (0.56) | NPC1RAB9ASMN1; SMN2MAOBLMNA | |
| SCHEMBL498716 | 0.74 | PRPS1 (0.45) | SMN1; SMN2L3MBTL1NR4A2LMNAKMT2A | |
| SCHEMBL21122759 | 0.74 | SRD5A2 (0.55) | NPC1RAB9ALTB4RLTB4R2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| EP-1945217-B1 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | disclosed |
| US-8026247-B2 | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2011-09-27 | — | — | US | disclosed |
| CN-101693709-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG | 2010-04-14 | — | — | CN | disclosed |
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | NOVARTIS AG | 2008-12-11 | — | — | US | disclosed |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | NOVARTIS AG (CH) | 2008-11-20 | — | — | US | disclosed |
| CN-101304747-A | Combinations comprising a VEGF receptor inhibitor and a penetration enhancer | NOVARTIS AG (CH) | 2008-11-12 | — | — | CN | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| CN-101018784-A | Bicyclic amides as kinase inhibitors | NOVARTIS AG (CH) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306058-A1 | Combinations Comprising a Vegf Receptor Inhibitor | KDR, FLT4, FLT1 | NPC1 1208/4885RAB9A 3765/4885SMN1; SMN2 4483/4885 |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | NPC1 2499/4885RAB9A 1861/4885SMN1; SMN2 3726/4885 |
| US-20080287427-A1 | Bicyclic Amides as Kinase Inhibitors | MAP3K20, MAP3K1, MAP3K19 | NPC1 2676/4885RAB9A 1808/4885SMN1; SMN2 3853/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | NPC1 1208/4885RAB9A 3765/4885SMN1; SMN2 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.